• 1
    Kearny PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217223.
  • 2
    Lasek R, Mueller-Oerlinghausen B, Berthold HK, Tiaden JD, eds. Recommendations for the Therapy of Arterial Hypertension, 2nd ed. 2004 (in German). Drug Commission of the German Medical Association. Accessed February 17, 2012.
  • 3
    Die Deutsche Hochdruckliga e.V. DHL-Deutsche Hypertonie Gesellschaft. Leitlinien zur Behandlung der arteriellen Hypertonie. 2008. Acces-sed February 17, 2011.
  • 4
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003;289:25602572.
  • 5
    Sawicki PT, McGauran N. Have ALLHAT, ANBP2, ASCOT-BPLA, and so forth improved our knowledge about better hypertension care? Hypertension. 2006;48:17.
  • 6
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.
  • 7
    Institute for Quality and Efficiency in Health Care (IQWiG). Vergleichende Nutzenbewertung verschiedener antihypertensiver Wirkstoffgruppen als Therapie der ersten Wahl bei Patienten mit essentieller Hypertonie. IQWiG-Bericht Jahr 2009, Nr. 44. Accessed February 17, 2012.
  • 8
    Hasford J, Schröder-Bernhardi D, Rottenkolber M, et al. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol. 2007;63:10551061.
  • 9
    Patel BV, Remigio-Baker RA, Mehta D, et al. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens (Greenwich). 2007;9:692700.
  • 10
    Patel BV, Remigio-Baker RA, Thiebaud P, et al. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy. BMC Fam Pract. 2008;9:61.
  • 11
    Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med. 2009;361:21532164.
  • 12
    Kuehlein T, Laux G, Gutscher A, et al. Diuretics for hypertension-an inconsistency in primary care prescribing behaviour. Curr Med Res Opin. 2011;27:497502.
  • 13
    Laux G, Koerner T, Rosemann T, et al. The CONTENT project: a problem-oriented, episode based electronic patient record in primary care. Inform Prim Care. 2005;13:249255.
  • 14
    Mayring P. Qualitative Content Analysis-Basics and Techniques, 10th ed. Weinheim and Basel: Beltz; 2008.
  • 15
    Muhr T. ATLAS.ti 5.0-The Knowledge Workbench Scientific Software, 2nd ed. Berlin: Scientific Software Development; 2004.
  • 16
    Krippendorf K. Content Analysis. An Introduction to Its Methodology, 2nd ed. Beverly Hills: Sage Publications; 2004.
  • 17
    Glaser B, Strauss A. The Discovery of Grounded Theory. Strategies for Qualitative Research. New York: Aldine Pub; 1967.
  • 18
    Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin. 2008;24:23892401.
  • 19
    Kobalava ZD, Kotovskaya YV, Villevalde SV, et al. Treating hypertension by rational use of diuretics: results of the Russian ARGUS-2 Study. Curr Med Res Opin. 2009;25:22292237.
  • 20
    Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:21212158.
  • 21
    Ernst ME, Carter BL, Zheng S, Grimm RH Jr. Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens. 2010;23:440446.
  • 22
    Messerli FH, Makani H, Benjo A, et al. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol. 2011;57:590600.
  • 23
    Turnball F; for Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimes on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:15271535.
  • 24
    Fretheim A, Håvelsrud K, Oxman AD. Rational Prescribing in Primary care (RaPP): process evaluation of an intervention to improve prescribing of antihypertensive and cholesterol-lowering drugs. Implement Sci. 2006;1:19.
  • 25
    Tu K, Campbell NR, Chen Z, McAlister FA. Thiazide diuretics for hypertension: prescribing practices and predictors of use in 194,761 elderly patients with hypertension. Am J Geriatr Pharmacother. 2006;4:161167.
  • 26
    Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48:219224.
  • 27
    Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich). 2011;13:639643.
  • 28
    Grimm RH Jr, Grandits GA, Cutler JA, et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med. 1997;157:638648.
  • 29
    Wagner N, Pittrow D, Kirch W, et al. The use of guidelines in the primary care management of hypertension and diabetes. Soz Praventivmed. 2004;49:261268.
  • 30
    Bölter R, Kühlein T, Ose D, et al. Barriers to evidence-based medicine encountered among GPs-an issue based on misunderstanding? A qualitative study in the general practice setting. Z Evid Fortbild Qual Gesundhwes. 2010;104:661666.
  • 31
    Poluzzi E, Strahinja P, Vargiu A, et al. Initial treatment of hypertension and adherence to therapy in general practice in Italy. Eur J Clin Pharmacol. 2005;61:603609.
  • 32
    Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens. 2010;28:15841590.
  • 33
    Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399407.
  • 34
    Schwabe U, Paffrath D (eds). Arzneiverordnungsreport 2010. Heidelberg: Springer Medizin Verlag; 2010.
  • 35
    Abaci A, Kozan O, Oquz A, et al. Prescribing pattern of antihypertensive drugs in primary care units in Turkey: results from the TURKSAHA study. Eur J Clin Pharmacol. 2007;63:397402.
  • 36
    Wallenius S, Kumpusalo E, Pärnänen H, Takala J. Drug treatment for hypertension in Finnish primary health care. Eur J Clin Pharmacol. 1998;54:793799.
  • 37
    McManus RJ, Ryan R, Jones M, et al. How representative of primary care are research active practices? Cross-sectional survey. Fam Pract. 2008;25:5662.
  • 38
    Wetzel D, Himmel W, Heidenreich R, et al. Participation in a quality of care study and consequences for generalizability of general practice research. Fam Pract. 2005;22:458464.
  • 39
    Lam A. Tacit knowledge, organizational learning and societal institutions: an integrated framework. Organ Stud. 2000;21:487513.